HPV vaccination and anal HPV infection in gay, bisexual, and other men who have sex with men.

Autor: Kassam P; Division of Cancer Epidemiology, McGill University, Montréal, Quebec, Canada., El-Zein M; Division of Cancer Epidemiology, McGill University, Montréal, Quebec, Canada., Tota JE; Department of Oncology, McGill University, Montréal, Quebec, Canada; Epidemiology Department, Merck & Co., Inc., Rahway, NJ, USA., Tellier PP; Department of Family Medicine, McGill University, Montreal, Quebec, Canada., Coutlée F; Laboratoire de virologie moléculaire, Centre de recherche, Centre hospitalier de l' Université de Montréal (CRCHUM), et Département de Microbiologie, infectiologie et Immunologie, Université de Montréal, Montréal, Québec, Canada., de Pokomandy A; Department of Family Medicine, McGill University, Montreal, Quebec, Canada; Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada., Franco EL; Division of Cancer Epidemiology, McGill University, Montréal, Quebec, Canada. Electronic address: eduardo.franco@mcgill.ca.
Jazyk: angličtina
Zdroj: Vaccine [Vaccine] 2024 Dec 20; Vol. 45, pp. 126644. Date of Electronic Publication: 2024 Dec 20.
DOI: 10.1016/j.vaccine.2024.126644
Abstrakt: Background: Gay, bisexual, and other men who have sex with men (gbMSM) have a higher risk of human papillomavirus (HPV) infection and related diseases and would benefit from preventive measures such as HPV vaccination. We assessed the association between HPV vaccination and anal HPV infection in HIV-negative gbMSM and gbMSM living with HIV from the Lubricant Investigation in Men to Inhibit Transmission of HPV Infection study.
Methods: Participants attended 7 visits over 12 months where they provided a nurse-collected anal sample and self-completed a questionnaire on risk factors and HPV vaccination. Samples were tested for HPV using polymerase chain reaction assays. We assessed the association with HPV vaccination and anal HPV prevalence and incidence using logistic and Cox regression, respectively. Analyses at the individual- (unit of analysis = participant) and HPV-level (unit of analysis = HPV type) considered vaccine-targeted types (any of HPVs 6/11/16/18) as the outcome. To assess construct validity, we repeated analyses considering incidence of non-vaccine-targeted (within- and cross-species) HPV types at the HPV-level. Estimates were adjusted for a propensity score to predict cumulative HPV positivity based on selected study and participant characteristics.
Results: Of 258 enrolled participants (18.2-71.7 years; 69 being HIV-positive), 23.3 % were vaccinated at baseline. At the individual-level, there was no association between vaccination and HPVs 6/11/16/18 prevalence (n = 250, aOR = 1.12, 95 % CI = 0.56-2.22) or incidence (n = 152, aHR = 0.34, 95 % CI = 2.19 × 10 -18 -1.38). At the HPV-level, while there was no association with HPVs 6/11/16/18 prevalence (n = 1000, aOR = 0.99, 95 % CI = 0.57-1.71), vaccination was associated with a reduction in HPVs 6/11/16/18 incidence (n = 754, aHR = 0.22, 95 % CI = 6.01 × 10 -18 -0.79). Vaccination was not associated with incidence of within-species (n = 2299, aHR = 0.76, CI = 0.42-1.24) or cross-species (n = 3774, aHR = 1.28, CI = 0.89-1.85) HPV types. Results were similar by HIV status.
Conclusion: Our findings support that HPV vaccination protects against incident anal infection of vaccine-targeted HPV types, thus, gbMSM should be encouraged to get vaccinated against HPV.
Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Eduardo L. Franco reports financial support was provided by Canadian Institutes of Health Research. Alexandra de Pokomandy reports financial support was provided by Canadian Institutes of Health Research. Eduardo L. Franco reports financial support was provided by Canadian Cancer Society Research Institute. Francois Coutlee reports financial support was provided by Fonds de la recherche en Sante du Quebec. Alexandra de Pokomandy reports financial support was provided by Fonds de la recherche en Sante du Quebec. Eduardo L. Franco reports equipment, drugs, or supplies was provided by CarraShield Labs. Eduardo L. Franco reports financial support was provided by Merck Canada. Eduardo L. Franco reports a relationship with Merck that includes: consulting or advisory. Eduardo L. Franco reports a relationship with GSK that includes: consulting or advisory. Eduado L. Franco reports a relationship with Roche Diagnostics that includes: consulting or advisory. Alexandra de Pokomandy reports a relationship with ViiV Healthcare that includes: consulting or advisory. Francois Coutlee reports a relationship with Merck Sharp & Dohme Corp that includes: funding grants and speaking and lecture fees. Francois Coutlee reports a relationship with Benton Dickinson that includes: funding grants. Francois Coutlee reports a relationship with Roche Diagnostics that includes: consulting or advisory and speaking and lecture fees. Joseph E. Tota reports a relationship with Merch Sharp & Dohme LLC that includes: employment. Eduardo L. Franco has patent DNA methylation markers for early detection of cervical cancer pending to Office of Innovation and Partnerships, McGill University, Montreal, Quebec, Canada. Mariam El-Zein has patent DNA methylation markers for early detection of cervical cancer pending to Office of Innovation and Partnerships, McGill University, Montreal, Quebec, Canada. ELF served as a Steering Committee Member for a publicly funded study in Finland that received support from GSK. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: